Moderna (NASDAQ:MRNA) Price Target Lowered to $231.00 at The Goldman Sachs Group

Moderna (NASDAQ:MRNA) had its price target trimmed by The Goldman Sachs Group from $269.00 to $231.00 in a research report sent to investors on Friday, Benzinga reports. The firm currently has a buy rating on the stock.

MRNA has been the subject of a number of other research reports. Argus lowered their target price on Moderna from $160.00 to $140.00 and set a buy rating for the company in a report on Wednesday, September 13th. HSBC raised Moderna from a reduce rating to a hold rating and reduced their price target for the stock from $89.00 to $69.00 in a research report on Friday. William Blair began coverage on Moderna in a research report on Monday, July 24th. They set a market perform rating and a $136.28 price target on the stock. Morgan Stanley reduced their price target on Moderna from $128.00 to $123.00 and set an equal weight rating on the stock in a research report on Friday, August 4th. Finally, Deutsche Bank Aktiengesellschaft downgraded Moderna from a hold rating to a sell rating and reduced their price target for the stock from $125.00 to $60.00 in a research report on Thursday, November 2nd. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of Hold and a consensus price target of $143.02.

Moderna Stock Down 7.0 %

Moderna stock opened at $72.07 on Friday. The business has a fifty day moving average of $96.96 and a two-hundred day moving average of $113.25. The company has a quick ratio of 3.16, a current ratio of 2.46 and a debt-to-equity ratio of 0.04. The firm has a market cap of $27.43 billion, a P/E ratio of -7.71 and a beta of 1.70. Moderna has a twelve month low of $62.55 and a twelve month high of $217.25.

Insider Activity at Moderna

In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $115.51, for a total value of $1,732,650.00. Following the sale, the director now directly owns 2,012,209 shares of the company’s stock, valued at $232,430,261.59. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $115.51, for a total value of $1,732,650.00. Following the sale, the director now directly owns 2,012,209 shares of the company’s stock, valued at $232,430,261.59. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO James M. Mock sold 2,858 shares of the company’s stock in a transaction on Friday, October 6th. The shares were sold at an average price of $102.50, for a total transaction of $292,945.00. Following the completion of the sale, the chief financial officer now directly owns 2,952 shares in the company, valued at $302,580. The disclosure for this sale can be found here. Insiders have sold a total of 179,912 shares of company stock valued at $18,596,893 in the last ninety days. Company insiders own 15.70% of the company’s stock.

Institutional Investors Weigh In On Moderna

Several hedge funds have recently modified their holdings of the company. Reik & CO. LLC boosted its stake in shares of Moderna by 11.7% during the 3rd quarter. Reik & CO. LLC now owns 4,780 shares of the company’s stock worth $494,000 after acquiring an additional 500 shares in the last quarter. Wealthspire Advisors LLC boosted its stake in shares of Moderna by 88.7% during the 3rd quarter. Wealthspire Advisors LLC now owns 3,289 shares of the company’s stock worth $340,000 after acquiring an additional 1,546 shares in the last quarter. Privium Fund Management B.V. boosted its stake in shares of Moderna by 43.6% during the 3rd quarter. Privium Fund Management B.V. now owns 43,861 shares of the company’s stock worth $4,530,000 after acquiring an additional 13,310 shares in the last quarter. Retirement Systems of Alabama boosted its stake in shares of Moderna by 0.5% during the 3rd quarter. Retirement Systems of Alabama now owns 74,868 shares of the company’s stock worth $7,733,000 after acquiring an additional 358 shares in the last quarter. Finally, Sfmg LLC boosted its stake in shares of Moderna by 41.0% during the 3rd quarter. Sfmg LLC now owns 2,408 shares of the company’s stock worth $249,000 after acquiring an additional 700 shares in the last quarter. 64.51% of the stock is owned by hedge funds and other institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.